10,954 Shares in Inogen, Inc. (NASDAQ:INGN) Bought by Verition Fund Management LLC

Verition Fund Management LLC bought a new position in shares of Inogen, Inc. (NASDAQ:INGN) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,954 shares of the medical technology company’s stock, valued at approximately $106,000.

Other large investors also recently bought and sold shares of the company. Divisadero Street Capital Management LP increased its stake in shares of Inogen by 682.3% during the 2nd quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company’s stock worth $19,079,000 after purchasing an additional 2,046,766 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Inogen by 312.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock valued at $1,694,000 after buying an additional 132,287 shares during the last quarter. AQR Capital Management LLC increased its position in Inogen by 29.3% during the second quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company’s stock worth $4,642,000 after buying an additional 129,307 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in shares of Inogen in the second quarter worth $651,000. Finally, Monaco Asset Management SAM purchased a new stake in shares of Inogen in the second quarter valued at $610,000. Institutional investors and hedge funds own 89.94% of the company’s stock.

Inogen Stock Down 0.1 %

Shares of NASDAQ:INGN opened at $8.95 on Tuesday. The firm has a 50-day simple moving average of $9.50 and a 200 day simple moving average of $9.73. Inogen, Inc. has a fifty-two week low of $5.08 and a fifty-two week high of $13.33. The company has a market cap of $213.17 million, a PE ratio of -3.98 and a beta of 1.02.

Analyst Upgrades and Downgrades

Several analysts have commented on INGN shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a research note on Friday, November 8th. StockNews.com raised Inogen from a “hold” rating to a “buy” rating in a research report on Thursday, December 12th.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.